Shijiazhuang Yiling Pharmaceutical (002603) Q3 2024 earnings summary

Executive summary

• Revenue for Q3 2024 was ¥1.76 billion, down 1.3% year-over-year; YTD revenue was ¥6.37 billion, down 25.76% year-over-year.

• Net profit attributable to shareholders in Q3 was ¥24.32 million, down 84.07% year-over-year; YTD net profit was ¥554.78 million, down 68.46% year-over-year.

• Cash flow from operating activities in Q3 increased 123.08% year-over-year to ¥322.63 million.

Financial highlights

• Gross margin and operating income declined significantly compared to the same period last year.

• Basic and diluted EPS for Q3 were ¥0.0146, down 84.03% year-over-year; YTD EPS was ¥0.3321, down 68.45%.

• Total assets at Q3-end were ¥16.61 billion, down 2.15% from year-end 2023.

• Owner's equity attributable to shareholders was ¥11.50 billion, up 0.47% from year-end.

Key financial ratios and metrics

• Weighted average ROE for Q3 was 0.27%, down 1.25 percentage points year-over-year; YTD ROE was 4.80%, down 10.57 percentage points.

• Net profit margin and cash conversion improved due to reduced operating expenses.